Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation

Leukemia and Lymphoma

Volumn 49, Issue 4, 2008, Pages 727-733

  Crocchiolo, Roberto ^a   Canevari, Carla ^a   Assanelli, Andrea ^a   Lunghi, Francesca ^a   Tassara, Michela ^a   Stanghellini, Maria Lupo ^a   Clerici, Daniela ^a   Landoni, Claudio ^a   Servida, Paolo ^a   Bernardi, Massimo ^a   Peccatori, Jacopo ^a   Ferreri, Andres ^a   Gianolli, Luigi ^a   Bordignon, Claudio ^a   Caligaris Cappio, Federico ^a   Ciceri, Fabio ^a   Fazio, Ferruccio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

18FDG PET; Autologous stem cell transplantation; High dose sequential chemotherapy; Lymphoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MELPHALAN; METHOTREXATE; RITUXIMAB; ANTINEOPLASTIC AGENT;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; ADOLESCENT; ARTICLE; AUTOTRANSPLANTATION; EVALUATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; MORTALITY; PREOPERATIVE CARE; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUORODEOXYGLUCOSE F18; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 42049123305     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701885545     Document Type: Conference Paper

References (38)

1. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H. and Bron, D. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333, pp. 1540-1545.
2. Anderson, J. R., Vose, J. M., Bierman, P. J., Weisenberger, D. D., Sanger, W. G. and Pierson, J. (1993) Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group. J Clin Oncol, 11, pp. 218-224.
3. Philip, T., Armitage, J. O., Spitzer, G., Chauvin, F., Jagannath, S. and Cahn, J. Y. (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med, 316, pp. 1493-1498.
4. Ferme, C., Mounier, N., Divine, M., Brice, P., Stamatoullas, A. and Reman, O. (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol, 20, pp. 467-475.
5. Moskowitz, C. H., Kewalramani, T., Nimer, S. D., Gonzalez, M., Zelenetz, A. D. and Yahalom, J. (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol, 124, pp. 645-652.
6. Tarella, C., Zanni, M., Nicola, M Di, Patti, C., Calvi, R. and Pescarollo, A. (2007) Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia, 21, p. 1802.11.
7. Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M. and Guermazi, A. (2007) Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol, 25, pp. 571-578.
8. Moog, F., Bangerter, M., Diederichs, C. G., Guhlmann, A., Kotzerke, J. and Merkle, E. (1997) Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro--glucose (FDG) PET in nodal staging. Radiology, 203, pp. 795-800.
9. Moog, F., Bangerter, M., Diederichs, C. G., Guhlmann, A., Merkle, E. and Frickhofen, N. (1998) Extranodal malignant lymphoma: Detection with FDG PET versus CT. Radiology, 206, pp. 475-481.
10. Schaefer, N. G., Strobel, K., Taverna, C. and Hany, T. F. (2007) Bone involvement in patients with lymphoma: The role of FDG-PET/CT. Eur J Nucl Med Mol Imaging, 34, pp. 60-67.
11. Hernandez-Maraver, D., Hernandez-Navarro, F., Gomez-Leon, N., Coya, J., Rodriguez-Vigil, B. and Madero, R. (2006) Positron emission tomography/ computed tomography: Diagnostic accuracy in lymphoma. Br J Haematol, 135, pp. 293-302.
12. Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J. and Vandenberghe, P. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol, 19, pp. 414-419.
13. Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P. and Rigo, P. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica, 85, pp. 613-618.
14. Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O. and Lammertsma, A. A. (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer, 35, pp. 1773-1782.
15. Romer, W., Hanauske, A. R., Ziegler, S., Thodtmann, R., Weber, W. and Fuchs, C. (1998) Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood, 91, pp. 4464-4471.
16. Juweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y. and Wooldridge, J. E. (2005) Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol, 23, pp. 4652-4661.
17. Freudenberg, L. S., Antoch, G., Schutt, P., Beyer, T., Jentzen, W. and Muller, S. P. (2004) FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging, 31, pp. 325-329.
18. Zinzani, P. L., Musuraca, G., Alinari, L., Fanti, S., Tani, M. and Stefoni, V. (2007) Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma, 7, pp. 291-295.
19. Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P. and Rigo, P. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 94, pp. 429-433.
20. Querellou, S., Valette, F., Bodet-Milin, C., Oudoux, A., Carlier, T. and Harousseau, J. L. (2006) FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol, 85, pp. 759-767.
21. Gallamini, A., Rigacci, L., Merli, F., Nassi, L., Bosi, A. and Capodanno, I. (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica, 91, pp. 475-481.
22. Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T. and Jurlander, J. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, pp. 52-59.
23. Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J. D. and Belhadj, K. (2005) [18F]fluoro-2-deoxy--glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood, 106, pp. 1376-1381.
24. Hutchings, M., Loft, A., Hansen, M., Berthelsen, A. K. and Specht, L. (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol, 78, pp. 206-212.
25. Schot, B. W., Zijlstra, J. M., Sluiter, W. J., van Imhoff, G. W., Pruim, J. and Vaalburg, W. (2007) Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood, 109, pp. 486-491.
26. A predictive model for aggressive non-Hodgkin's lymphoma (1993) The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med, 329, pp. 987-994.
27. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
28. Kaplan, E. L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
29. Mantel, M. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, pp. 163-170.
30. Cox, D. R. (1972) Regression models and life tables. J R Stat Soc, 34, pp. 187-220.
31. Schot, B. W., Pruim, J., van Imhoff, G. W., Sluiter, W. J., Vaalburg, W. and Vellenga, E. (2006) The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica, 91, pp. 490-495.
32. Filmont, J. E., Czernin, J., Yap, C., Silverman, D. H., Quon, A. and Phelps, M. E. (2003) Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest, 124, pp. 608-613.
33. Svoboda, J., Andreadis, C., Elstrom, R., Chong, E. A., Downs, L. H. and Berkowitz, A. (2006) Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant, 38, pp. 211-216.
34. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J. and Bormans, G. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 102, pp. 53-59.
35. Becherer, A., Mitterbauer, M., Jaeger, U., Kalhs, P., Greinix, H. T. and Karanikas, G. (2002) Positron emission tomography with [18F]2-fluoro--2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia, 16, pp. 260-267.
36. Jabbour, E., Hosing, C., Ayers, G., Nunez, R., Anderlini, P. and Pro, B. (2007) Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer, 109, pp. 2481-2489.
37. Filmont, J. E., Gisselbrecht, C., Cuenca, X., Deville, L., Ertault, M. and Brice, P. (2007) The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer, 110, pp. 1361-1369.
38. Corradini, P., Dodero, A., Farina, L., Fanin, R., Patriarca, F. and Miceli, R. (2007) Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: Pre-transplant disease status and histotype heavily influence outcome. Leukemia, 21, pp. 2316-2323.